

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6049653/jiri-tomasek-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18 papers	939 citations	8 h-index	18 g-index
18 ext. papers	1,137 ext. citations	6.2 avg, IF	3 L-index

#	Paper	IF	Citations
18	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2016 , 387, 968-977	40	694
17	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1411-1422	21.7	49
16	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , 2016 , 115, 974-982	8.7	44
15	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. <i>Cancer Science</i> , 2018 , 109, 174-181	6.9	42
14	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017 , 17, 132-144	3.2	36
13	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 237-245	5.6	32
12	Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 121-121	2.2	15
11	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA5-LBA5	2.2	10
10	Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. <i>BMC Cancer</i> , 2017 , 17, 798	4.8	5
9	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.. <i>Journal of Clinical</i>	2.2	3
8	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4029-4029	2.2	3
7	Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. <i>Future Oncology</i> , 2019 , 15, 1997-2007	3.6	2
6	Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. <i>Advances in Therapy</i> , 2019 , 36, 670-683	4.1	2
5	Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 276-276	2.2	2
4	Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 547-547	2.2	
3	Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4028-4028	2.2	
2	Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15197-e15197	2.2	

- 1 The liver function assessment: The indocyanine green retention in correlation with the cholescintigraphic measurement. Retrospective validation study in 107 patients with liver malignancies.. *Journal of Clinical Oncology*, **2013**, 31, 155-155 2.2